The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.

Colorectal cancer breaks the usual immune rules, with certain regulatory T cells linked to improved survival. In many solid ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...

When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had already spread to her stomach and liver. Even after a ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...

A new study from Memorial Sloan Kettering Cancer Center finds that in colorectal cancer, not all regulatory T cells are created equal. One subtype suppresses cancer growth while another aids it. The ...

This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...